Cidara Therapeutics Inc (CDTX) Shares Rise Despite Market Challenges

Cidara Therapeutics Inc (NASDAQ: CDTX) has experienced a rise in its stock price by 10.56 compared to its previous closing price of 0.97. However, the company has seen a gain of 43.35% in its stock price over the last five trading days. Zacks Investment Research reported 2023-12-26 that Cidara’s (CDTX) Rezzayo (rezafungin acetate) gets approval from the European Commission for the treatment of invasive candidiasis in adults. The stock rises 11.1%.

Is It Worth Investing in Cidara Therapeutics Inc (NASDAQ: CDTX) Right Now?

Company’s 36-month beta value is 1.01.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 5 as “overweight,” 1 as “hold,” and 0 as “sell.”

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

The public float for CDTX is 81.35M, and currently, short sellers hold a 0.22% ratio of that floaft. The average trading volume of CDTX on April 03, 2024 was 560.11K shares.

CDTX’s Market Performance

CDTX’s stock has seen a 43.35% increase for the week, with a 50.24% rise in the past month and a 34.76% gain in the past quarter. The volatility ratio for the week is 15.37%, and the volatility levels for the past 30 days are at 8.80% for Cidara Therapeutics Inc The simple moving average for the past 20 days is 44.76% for CDTX’s stock, with a 25.35% simple moving average for the past 200 days.

Analysts’ Opinion of CDTX

Many brokerage firms have already submitted their reports for CDTX stocks, with H.C. Wainwright repeating the rating for CDTX by listing it as a “Buy.” The predicted price for CDTX in the upcoming period, according to H.C. Wainwright is $6 based on the research report published on December 03, 2021 of the previous year 2021.

WBB Securities, on the other hand, stated in their research note that they expect to see CDTX reach a price target of $6.25. The rating they have provided for CDTX stocks is “Strong Buy” according to the report published on September 22nd, 2021.

Aegis Capital gave a rating of “Buy” to CDTX, setting the target price at $9 in the report published on March 04th of the previous year.

CDTX Trading at 50.68% from the 50-Day Moving Average

After a stumble in the market that brought CDTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -27.70% of loss for the given period.

Volatility was left at 8.80%, however, over the last 30 days, the volatility rate increased by 15.37%, as shares surge +51.34% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +49.48% upper at present.

During the last 5 trading sessions, CDTX rose by +43.35%, which changed the moving average for the period of 200-days by -6.96% in comparison to the 20-day moving average, which settled at $0.7573. In addition, Cidara Therapeutics Inc saw 34.76% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at CDTX starting from Tari Leslie, who sale 21,029 shares at the price of $0.67 back on Mar 11 ’24. After this action, Tari Leslie now owns 258,681 shares of Cidara Therapeutics Inc, valued at $14,085 using the latest closing price.

Sandison Taylor, the Chief Medical Officer of Cidara Therapeutics Inc, sale 20,662 shares at $0.67 during a trade that took place back on Mar 11 ’24, which means that Sandison Taylor is holding 347,095 shares at $13,839 based on the most recent closing price.

Stock Fundamentals for CDTX

Current profitability levels for the company are sitting at:

  • -0.56 for the present operating margin
  • 0.98 for the gross margin

The net margin for Cidara Therapeutics Inc stands at -0.55. The total capital return value is set at -1.14. Equity return is now at value -366.84, with -48.15 for asset returns.

Based on Cidara Therapeutics Inc (CDTX), the company’s capital structure generated 0.35 points at debt to capital in total, while cash flow to debt ratio is standing at -7.05. The debt to equity ratio resting at 0.54. The interest coverage ratio of the stock is -31.96.

Currently, EBITDA for the company is -29.72 million with net debt to EBITDA at 1.4. When we switch over and look at the enterprise to sales, we see a ratio of 0.93. The receivables turnover for the company is 19.8for trailing twelve months and the total asset turnover is 0.89. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.62.

Conclusion

In a nutshell, Cidara Therapeutics Inc (CDTX) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.

Related Posts